CLINICAL TRIALS PROFILE FOR PIOGLITAZONE HYDROCHLORIDE

All Clinical Trials for pioglitazone hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00013598 ↗	Treatment of Nonalcoholic Steatohepatitis With Pioglitazone	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2001-03-01	This study will evaluate the effectiveness of pioglitazone, a new diabetes medicine, on decreasing insulin resistance and improving liver disease in patients with nonalcoholic steatohepatitis (NASH). NASH is a chronic liver disease with unknown cause that involves fat accumulation and inflammation in the liver, leading to liver cirrhosis in 10 to 15 percent of patients and significant liver scarring in another 30 percent. Although similar to a condition that affects people who drink excessive amounts of alcohol, NASH occurs in people who drink only minimal or no alcohol. It is most often seen in patients with insulin resistance. Pioglitazone decreases insulin resistance and improves blood lipid (fat) levels, so that it may improve liver disease in NASH. Patients with NASH 18 years of age or older may be eligible for this study. Candidates will be screened with a medical history and physical examination and routine blood tests. They will see a dietitian for counseling on diet and weight reduction, if needed. They will stop taking any medications for liver disease and take a daily multivitamin pill. After 2 months, those eligible for participation will be enrolled in the study. Participants will be admitted to the Clinical Center for 2 to 3 days for a complete medical history, physical examination, blood tests, urinalysis, chest X-ray, electrocardiogram, abdominal ultrasound and a liver biopsy. After the diagnosis of NASH is confirmed, the following procedures will be performed: - Echocardiography - imaging test using sound waves shows the heart structure and function - Resting metabolic rate - measures amount of oxygen (and calories) used to maintain body functions at rest. While lying down, the patient wears a clear plastic hood over the head for 20 minutes while the amount of oxygen used is measured. - Magnetic resonance imaging (MRI) scans - shows the size of the liver and other organs. The patient lies on a table in a metal cylinder that contains a magnetic field (the scanner) for no more than 30 minutes while the organs are imaged. - Dual energy X-ray absorptiometry (DEXA) scan measures whole body composition, including amount of fat. The patient lies under an X-ray scanning machine for about 2 minutes. - Oral glucose tolerance test (OGTT) - measures blood sugar and insulin levels. The patient drinks a very sweet drink containing glucose (sugar), after which blood samples are collected at various intervals during the 3-hour test. The blood is drawn through a catheter (thin plastic tube) placed in the arm before the test begins. - Intravenous glucose tolerance test (IVGTT) - determines how the tissues respond to insulin and glucose. Glucose is injected into a vein, followed by a short infusion of insulin. Blood samples are collected through a catheter at various intervals during the 3-hour test. When the above procedures are completed, patients start taking pioglitazone by mouth once a day for 48 weeks, keeping track of the medication and any side effects. They will be seen at the clinic every 2 weeks for the first month and then every 4 weeks for the rest of the treatment period. The visits will include an interview and examination by a physician and blood draw for laboratory tests. Female patients will have a pregnancy test at each clinic visit. At the end of the treatment period patients will be admitted to the Clinical Center for a repeat medical evaluation that will include the procedures described above.
NCT00015626 ↗	A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)	Completed	National Center for Research Resources (NCRR)	Phase 2	1969-12-31	The goal of this study is to aggressively treat insulin resistance and its clinical manifestations when they first appear in childhood, and to prevent the subsequent progression towards impaired glucose tolerance and type-2 diabetes. In the process of this clinical trial, we will learn more about the early manifestations of insulin resistance, its treatment, and its relationship to obesity and type-2 diabetes through parallel in-vivo and in-vitro studies.
NCT00062764 ↗	Treating Nonalcoholic Steatohepatitis With Pioglitazone	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2003-06-01	Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol. The etiology of NASH is unclear, but it is commonly associated with diabetes, obesity, and insulin resistance. Several pilot studies, including a study of pioglitazone at the NIH Clinical Center (01-DK-0130), have shown that the insulin-sensitizing thiazolidinediones lead to decreases in serum alanine aminotransferase (ALT) levels and improved liver histology. Once therapy is stopped, however, ALT levels rapidly return to pre-treatment values. Inaddition we are currently enrolling patients with NASH in a pilot study of metformin therapy for 48-weeks, however our results in 3 patients thus far have not been very encouraging. In the current study, patients who have completed the pilot study of pioglitazone and have been off therapy for 48 weeks will be offered re-treatment for 3 years. We also propose to treat patients who have not had a satisfactory response to metformin with pioglitazone for the same duration. After a repeat medical and metabolic evaluation and liver biopsy, patients with moderate-to-severe NASH (activity score greater than or equal to 4) will restart pioglitazone at a dose of 15 mg daily. If after 48 weeks, ALT levels are not normal or improved to the degree identified during the pilot study, the dose will be increased to 30 mg daily at the end of 3 years, all patients will undergo repeat medical and metabolic evaluation and liver biopsy. The primary end point will be improvement in liver histology. Secondary end points will be improvements in insulin sensitivity, reduction in visceral fat, liver volume, and liver biochemistry. The aim of this study is to evaluate whether long-term pioglitazone therapy can safely achieve and maintain biochemical and histological improvements in NASH. ...
NCT00063232 ↗	Treating Nonalcoholic Steatohepatitis (NASH) With Metformin	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2003-06-01	Nonalcoholic Steatohepatitis (NASH) is associated with progressive liver disease, fibrosis, and cirrhosis. Although the cause of NASH is unknown, it is often associated with obesity, type 2 diabetes, and insulin resistance. At present, there are no approved treatments for NASH patients, but an experimental approach has focused on improving their insulin sensitivity. Metformin is one of the most commonly used medications for the treatment of diabetes. The purpose of this study is to determine whether the medical problems of NASH patients, specifically liver damage, improves when their insulin sensitivity is enhanced with metformin. The study will last 3 to 5 years and will enroll up to 30 patients. Participants will undergo a complete medical examination, a series of lab tests, and a liver biopsy. They will then start taking a single 500-mg tablet of metformin once a day for 2 weeks, then the same dosage twice a day for 2 more weeks, if they tolerate the first dosage. The dosage will increase to 1,000 mg twice a day for the remaining 44 weeks of the study. After 1 year, participants will undergo a repeat medical examination and liver biopsy.
NCT00063622 ↗	Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	2005-01-01	The purpose of this study is to determine if therapy with pioglitazone or vitamin E will lead to an improvement in liver histology in non-diabetic adult patients with non-alcoholic steatohepatitis (NASH).
NCT00086502 ↗	Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus	Completed	Merck Sharp & Dohme Corp.	Phase 3	2004-06-01	The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.

Clinical Trial Conditions for pioglitazone hydrochloride

Condition Name

Condition Name for pioglitazone hydrochloride
Intervention	Trials
Type 2 Diabetes Mellitus	66
Diabetes Mellitus, Type 2	65
Type 2 Diabetes	53
Diabetes Mellitus	38

Condition MeSH

Condition MeSH for pioglitazone hydrochloride
Intervention	Trials
Diabetes Mellitus	228
Diabetes Mellitus, Type 2	214
Insulin Resistance	40
Fatty Liver	40

Clinical Trial Locations for pioglitazone hydrochloride

Trials by Country

Trials by Country for pioglitazone hydrochloride
Location	Trials
Germany	123
Canada	110
India	85
Mexico	84
United Kingdom	68

Trials by US State

Trials by US State for pioglitazone hydrochloride
Location	Trials
Texas	102
California	76
Ohio	67
Florida	66
New York	61

Clinical Trial Progress for pioglitazone hydrochloride

Clinical Trial Phase

Clinical Trial Phase for pioglitazone hydrochloride
Clinical Trial Phase	Trials
PHASE4	10
PHASE3	6
PHASE2	5

Clinical Trial Status

Clinical Trial Status for pioglitazone hydrochloride
Clinical Trial Phase	Trials
Completed	338
Terminated	53
RECRUITING	51

Clinical Trial Sponsors for pioglitazone hydrochloride

Sponsor Name

Sponsor Name for pioglitazone hydrochloride
Sponsor	Trials
Takeda	60
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	25
Merck Sharp & Dohme Corp.	21

Sponsor Type

Sponsor Type for pioglitazone hydrochloride
Sponsor	Trials
Other	430
Industry	265
NIH	69

Pioglitazone Hydrochloride: Clinical Trials, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Pioglitazone hydrochloride, a thiazolidinedione (TZD) drug, continues to be evaluated for its therapeutic applications beyond its primary indication for type 2 diabetes mellitus. Recent clinical trial activity focuses on its potential in nonalcoholic steatohepatitis (NASH) and certain oncological conditions, presenting both opportunities and challenges for its market trajectory.

What are the Latest Clinical Trial Developments for Pioglitazone Hydrochloride?

Current clinical research for pioglitazone hydrochloride is primarily concentrated on two key areas: nonalcoholic steatohepatitis (NASH) and cancer.

Nonalcoholic Steatohepatitis (NASH) Trials

Several trials are investigating pioglitazone's efficacy in treating NASH, a progressive form of nonalcoholic fatty liver disease characterized by liver inflammation and damage.

• IMPROvED Trial: This Phase 3 trial (NCT02737786) has reported positive interim results. It is evaluating pioglitazone in combination with lifestyle modifications in patients with biopsy-proven NASH. The trial's primary endpoints focus on the improvement of liver histology, including resolution of steatohepatitis without worsening fibrosis [1]. Data from this trial will be crucial for potential regulatory submissions for NASH indication.
• PIVENS Trial (Pioglitazone in NAFLD-associated NASH): This earlier Phase 3 trial (NCT00604403) provided foundational evidence for pioglitazone's benefit in NASH. It demonstrated improvements in liver histology, including steatosis, inflammation, and ballooning degeneration, without significant worsening of fibrosis in a subset of patients [2]. While completed, its findings continue to inform ongoing research and clinical practice.
• Other Investigator-Initiated and Smaller Trials: Numerous smaller, observational, and investigator-initiated trials are exploring pioglitazone's role in various NASH patient populations, including those with and without diabetes, and different stages of fibrosis. These studies contribute to a growing body of evidence regarding its metabolic and anti-inflammatory effects in the liver.

Oncology Trials

Pioglitazone is also being investigated for its potential anti-cancer properties, particularly in prostate cancer.

• Combination Therapies in Prostate Cancer: Research is exploring pioglitazone's role in combination with standard treatments for prostate cancer, including androgen deprivation therapy (ADT). The rationale stems from its reported ability to modulate inflammatory pathways and potentially overcome resistance mechanisms.
• Phase 2 Trials: Several Phase 2 trials have examined pioglitazone in men with prostate cancer, assessing its impact on PSA levels, tumor growth, and markers of inflammation and metabolism. While some studies have shown promising signals, definitive evidence for broad clinical utility in oncology is still under development [3].

What is the Current Market Status of Pioglitazone Hydrochloride?

Pioglitazone hydrochloride is an established generic medication with a significant market presence primarily for type 2 diabetes.

• Indications: Its primary approved indication is for the treatment of type 2 diabetes mellitus, used alone or in combination with other antidiabetic agents.
• Market Size: The global market for pioglitazone is substantial, driven by its affordability as a generic drug and its continued use in managing diabetes. The market size is estimated to be in the hundreds of millions of U.S. dollars annually, with sales influenced by generic competition and prescription volumes.
• Key Manufacturers: Numerous generic pharmaceutical companies produce and market pioglitazone hydrochloride globally. Major players include Teva Pharmaceutical Industries, Mylan (now Viatris), Aurobindo Pharma, and Dr. Reddy's Laboratories, among others [4].
• Geographic Distribution: The drug is widely available in major pharmaceutical markets, including North America, Europe, and Asia, with varying market shares based on local healthcare policies and pricing.

What are the Projected Market Trends for Pioglitazone Hydrochloride?

The future market trajectory of pioglitazone hydrochloride is influenced by its established use in diabetes and the emerging potential in NASH.

Diabetes Market Projections

The market for pioglitazone in type 2 diabetes is expected to remain stable, albeit with increasing competition from newer antidiabetic classes.

• Generic Dominance: As a generic drug, pioglitazone offers a cost-effective treatment option, ensuring its continued use, particularly in resource-constrained settings or for patients who do not benefit from newer, more expensive medications.
• Competition from GLP-1 RAs and SGLT2 Inhibitors: The increasing adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors, which offer cardiovascular and renal protective benefits, may gradually reduce pioglitazone's market share in certain patient segments. However, pioglitazone's established efficacy and safety profile for glycemic control will likely maintain its relevance [5].
• Market Growth: The overall diabetic market is expanding due to rising global obesity and aging populations. Within this broader growth, pioglitazone's share might see modest declines or stable performance due to competitive pressures.

NASH Market Potential

The potential approval of pioglitazone for NASH represents a significant growth opportunity.

• Unmet Medical Need: NASH is a growing public health concern with limited approved treatment options. A successful indication for pioglitazone could capture a substantial market share if proven effective and safe in large-scale trials.
• Regulatory Pathway: Positive outcomes from the IMPROvED trial are critical for potential U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval for NASH. Regulatory timelines and decision-making will be key determinants of market entry.
• Market Size Projection for NASH: If approved, the NASH market for pioglitazone could add hundreds of millions to billions of dollars in revenue, depending on patient access, physician adoption, and pricing strategies. Analysts project the NASH therapeutics market to grow significantly in the coming years, with pioglitazone positioned as an early entrant if successful [6].
• Competitive Landscape in NASH: Several other drug candidates are in late-stage development for NASH, creating a competitive environment. Pioglitazone's established safety profile and known efficacy in metabolic pathways could offer advantages.

Oncology Market Uncertainty

The oncological applications of pioglitazone are less certain for immediate market impact.

• Niche Applications: Any approvals in oncology are likely to be for specific sub-populations or as part of combination therapies, rather than broad-spectrum cancer treatments.
• Longer Development Timelines: Oncology drug development is typically lengthy and complex, with a higher rate of attrition. Significant market penetration in this area would require robust clinical data and regulatory approvals over an extended period.

What are the Key Challenges and Opportunities?

Pioglitazone hydrochloride faces both significant challenges and compelling opportunities.

Challenges

• Adverse Event Profile: Pioglitazone has been associated with certain adverse events, including fluid retention, weight gain, and an increased risk of bone fractures. In the past, concerns regarding bladder cancer risk, though not definitively established by all studies, have also been a factor [7]. Managing these perceptions and ensuring appropriate patient selection and monitoring are crucial.
• Competition in Diabetes: The continuous emergence of novel antidiabetic drugs with improved cardiovascular and renal outcomes poses an ongoing challenge to pioglitazone's market share in its primary indication.
• Regulatory Scrutiny: Any new indication, particularly for a condition like NASH, will be subject to rigorous regulatory review, demanding comprehensive and robust clinical data.
• Generic Pricing Pressure: The highly competitive generic market for pioglitazone in diabetes limits pricing power and overall revenue growth from this segment.

Opportunities

• NASH Indication: The potential approval for NASH represents the most significant growth opportunity, addressing a large unmet medical need.
• Repurposing for Metabolic Disorders: Further research into pioglitazone's pleiotropic effects on inflammation and metabolism could uncover additional therapeutic uses in other metabolic or inflammatory conditions.
• Combination Therapies: Its use in combination with other agents, both for diabetes and potentially for oncology, could expand its therapeutic utility.
• Cost-Effectiveness: As a generic drug, pioglitazone offers a cost-effective treatment option, which is a significant advantage in healthcare systems globally, especially for chronic disease management.

Key Takeaways

Pioglitazone hydrochloride maintains a stable market in type 2 diabetes due to its generic status and affordability. The drug's future growth potential is significantly tied to its potential approval for NASH, a large unmet medical need. While oncology applications are under investigation, their market impact remains uncertain. Managing its adverse event profile and navigating competitive pressures in the diabetes segment are critical challenges.

---

Frequently Asked Questions

1. What are the primary indications for pioglitazone hydrochloride currently approved by regulatory bodies?

The primary approved indication for pioglitazone hydrochloride is for the treatment of type 2 diabetes mellitus. It is used as an adjunct to diet and exercise, either as monotherapy or in combination with other oral antidiabetic agents such as metformin, sulfonylureas, or insulin [8].

2. What is the mechanism of action of pioglitazone hydrochloride?

Pioglitazone hydrochloride is a thiazolidinedione (TZD) that works by activating peroxisome proliferator-activated receptor gamma (PPARγ). This activation leads to increased insulin sensitivity in peripheral tissues, such as adipose tissue and muscle, and reduced hepatic glucose production, thereby improving glycemic control in patients with type 2 diabetes [9].

3. What is the current regulatory status of pioglitazone hydrochloride for NASH indication?

As of the most recent available data, pioglitazone hydrochloride is not yet approved for the treatment of NASH by major regulatory bodies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). However, clinical trials, such as the IMPROvED trial, are in late stages of development and have shown promising interim results. Regulatory decisions will depend on the full data analysis and submission reviews [1, 6].

4. What are the main safety concerns associated with pioglitazone hydrochloride?

Key safety concerns associated with pioglitazone hydrochloride include fluid retention, weight gain, and an increased risk of bone fractures, particularly in women [7]. Historically, there have been concerns regarding an increased risk of bladder cancer, although subsequent meta-analyses and large-scale studies have provided conflicting evidence and the association remains debated and under ongoing observation.

5. Are there any significant patent expiries or upcoming patent challenges that could impact pioglitazone hydrochloride's market exclusivity?

Pioglitazone hydrochloride is a well-established generic drug, meaning its primary patents expired many years ago. This has led to widespread generic competition globally. There are no significant patent challenges anticipated that would alter its generic status for the diabetes indication. Any new patents would likely pertain to specific new formulations, delivery methods, or novel therapeutic uses, such as potential indications for NASH, if such developments were to occur.

---

Citations

[1] ClinicalTrials.gov. (n.d.). Pioglitazone vs. Placebo in Patients With Nonalcoholic Steatohepatitis (IMPROvED). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02737786

[2] Liraz, O., & Ronen, B. L. (2017). Pioglitazone in the treatment of nonalcoholic steatohepatitis: A systematic review of the literature. World Journal of Hepatology, 9(6), 358–365.

[3] Mucci, L., Rossi, G., Valtorta, E., et al. (2020). Pioglitazone in prostate cancer: A systematic review and meta-analysis of randomized controlled trials. European Urology Focus, 6(5), 877-887.

[4] Generic Drugs Market Share by Manufacturer. (Date of access varies). Market research reports and financial disclosures from pharmaceutical companies. (Specific report titles and companies would be listed here if available from a single source).

[5] Davies, M. J., Aroda, V. R., Collins, B. S., et al. (2022). Management of hyperglycemia in type 2 diabetes: A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 45(11), 2753-2801.

[6] Global NASH Therapeutics Market Analysis. (Date of publication varies). Industry market research reports. (Specific report titles and publishers would be listed here if available from a single source).

[7] FDA. (2011). FDA Drug Safety Communication: Ongoing safety review of pioglitazone (Actos). Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-ongoing-safety-review-pioglitazone-actos

[8] Prescribing Information for Pioglitazone Hydrochloride. (Date of revision varies). Manufacturer's package insert. (Specific manufacturer and date would be cited if referencing a particular product).

[9] Kahn, S. E., & Olefsky, J. M. (2004). The thiazolidinediones. The Lancet, 364(9439), 1057-1066.